About Pediatric Atopic Dermatitis
Atopic dermatitis, also known as eczema, affects millions of adults and children across the globe every day. While there is an estimated 5% of adults with atopic dermatitis in the world, it affects children at a much higher rate with up to 15-20% of all children struggling with eczema.1
Diagnosis of children with atopic dermatitis typically begins with a discussion with a healthcare provider after a parent or guardian notes symptoms. Symptoms of atopic dermatitis can include red and inflamed skin, scabs, scaling, and mild bleeding (due to scratching). A review of medical history and questions about health are usually the starting points of receiving a diagnosis. Usually, treatment starts with topical medicines such as corticosteroids. Unfortunately, some children do not respond well to treatment and are left with continued itchy and uncomfortable skin.
The ADorable1 study is currently studying a new investigational option known as lebrikizumab to see if it can help improve atopic dermatitis symptoms in children who are not gaining benefit from using standard medications.
Study Criteria
Interested in enrolling your child or young loved one in the Adorable1 Pediatric Atopic Dermatitis study? To participate in this study, children must*:
- Be 6 - <18 years of age
- Be clinically diagnosed with atopic dermatitis, also known as eczema, for at least one year
- Have a poor or unsatisfactory response using certain topical medications
Other criteria for eligibility apply. Study participants receive study-related medical exams and investigational drug at no cost. Compensation for time and travel may be available.*